Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 517 citing articles:

Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation
Kelly Moran-Crusio, Linsey B. Reavie, Alan H. Shih, et al.
Cancer Cell (2011) Vol. 20, Iss. 1, pp. 11-24
Open Access | Times Cited: 1215
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat, Domenica Caramazza, Rakhee Vaidya, et al.
Journal of Clinical Oncology (2010) Vol. 29, Iss. 4, pp. 392-397
Open Access | Times Cited: 977
Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice
Myunggon Ko, Hozefa S. Bandukwala, Jungeun An, et al.
Proceedings of the National Academy of Sciences (2011) Vol. 108, Iss. 35, pp. 14566-14571
Open Access | Times Cited: 554
Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
Ayalew Tefferi, Rakhee Vaidya, Domenica Caramazza, et al.
Journal of Clinical Oncology (2011) Vol. 29, Iss. 10, pp. 1356-1363
Open Access | Times Cited: 550
Single-Cell Exome Sequencing and Monoclonal Evolution of a JAK2-Negative Myeloproliferative Neoplasm
Yong Hou, Luting Song, Ping Zhu, et al.
Cell (2012) Vol. 148, Iss. 5, pp. 873-885
Open Access | Times Cited: 526
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Tiziano Barbui, Ayalew Tefferi, Alessandro M. Vannucchi, et al.
Leukemia (2018) Vol. 32, Iss. 5, pp. 1057-1069
Open Access | Times Cited: 491
RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group
Verena I. Gaidzik, Lars Bullinger, Richard F. Schlenk, et al.
Journal of Clinical Oncology (2011) Vol. 29, Iss. 10, pp. 1364-1372
Open Access | Times Cited: 438
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
Animesh Pardanani, Claire Harrison, Jorge E. Cortés, et al.
JAMA Oncology (2015) Vol. 1, Iss. 5, pp. 643-643
Closed Access | Times Cited: 412
New mutations and pathogenesis of myeloproliferative neoplasms
William Vainchenker, François Delhommeau, Stefan N. Constantinescu, et al.
Blood (2011) Vol. 118, Iss. 7, pp. 1723-1735
Open Access | Times Cited: 394
A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia
Apostolos Klinakis, Camille Lobry, Omar Abdel‐Wahab, et al.
Nature (2011) Vol. 473, Iss. 7346, pp. 230-233
Open Access | Times Cited: 376
Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations
Po−Ru Loh, Giulio Genovese, Robert E. Handsaker, et al.
Nature (2018) Vol. 559, Iss. 7714, pp. 350-355
Open Access | Times Cited: 349
Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies
Ayalew Tefferi, William Vainchenker
Journal of Clinical Oncology (2011) Vol. 29, Iss. 5, pp. 573-582
Closed Access | Times Cited: 318
Myeloproliferative Neoplasms
Ayalew Tefferi, Animesh Pardanani
JAMA Oncology (2015) Vol. 1, Iss. 1, pp. 97-97
Closed Access | Times Cited: 295
Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?
Hans Carl Hasselbalch
Blood (2012) Vol. 119, Iss. 14, pp. 3219-3225
Closed Access | Times Cited: 293
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Jorge E. Cortés, et al.
Nature Reviews Drug Discovery (2011) Vol. 10, Iss. 2, pp. 127-140
Closed Access | Times Cited: 284
Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance
Alfonso Quintás‐Cardama, Srđan Verstovšek
Clinical Cancer Research (2013) Vol. 19, Iss. 8, pp. 1933-1940
Open Access | Times Cited: 263
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients
Mrinal M. Patnaik, Raphaël Itzykson, Terra L. Lasho, et al.
Leukemia (2014) Vol. 28, Iss. 11, pp. 2206-2212
Closed Access | Times Cited: 257
EZH2 mutational status predicts poor survival in myelofibrosis
Paola Guglielmelli, Flavia Biamonte, Joannah Score, et al.
Blood (2011) Vol. 118, Iss. 19, pp. 5227-5234
Open Access | Times Cited: 256
DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies
Annie Im, Alison R. Sehgal, Martin Carroll, et al.
Leukemia (2014) Vol. 28, Iss. 9, pp. 1774-1783
Open Access | Times Cited: 251
Comprehensive mutational profiling in advanced systemic mastocytosis
Juliana Schwaab, Susanne Schnittger, Karl Sotlar, et al.
Blood (2013) Vol. 122, Iss. 14, pp. 2460-2466
Open Access | Times Cited: 244
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk‐stratification and management
Ayalew Tefferi, Tiziano Barbui
American Journal of Hematology (2015) Vol. 90, Iss. 2, pp. 162-173
Closed Access | Times Cited: 242
Ultra-sensitive Sequencing Identifies High Prevalence of Clonal Hematopoiesis-Associated Mutations throughout Adult Life
Rocío Acuña‐Hidalgo, Hilal Sengül, Marloes Steehouwer, et al.
The American Journal of Human Genetics (2017) Vol. 101, Iss. 1, pp. 50-64
Open Access | Times Cited: 236
Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?
Hans Carl Hasselbalch
Leukemia Research (2012) Vol. 37, Iss. 2, pp. 214-220
Closed Access | Times Cited: 230
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
Animesh Pardanani, Rebecca R. Laborde, Terra L. Lasho, et al.
Leukemia (2013) Vol. 27, Iss. 6, pp. 1322-1327
Open Access | Times Cited: 225
One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
Ayalew Tefferi, Terra L. Lasho, Thitina Jimma, et al.
Mayo Clinic Proceedings (2012) Vol. 87, Iss. 1, pp. 25-33
Open Access | Times Cited: 218
Page 1 - Next Page

Scroll to top